OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
The deal with unnamed large pharmaceutical company reportedly won’t include vaccine transport
BioLife Solutions, Inc.’s recently acquired SciSafe division has been awarded a two-year contract estimated at $2.7 million from an unnamed ‘large pharmaceutical company’ for cold chain management and storage of Covid-19 vaccines.
SciSafe, a provider of biological materials storage founded in 2010, maintains four cGMP-compliant facilities located in New Jersey, Massachusetts and Utah, with an expansion plan focused on the cell and gene therapy clusters located around the world.
While BioLife leadership did not name the pharmaceutical company in the $2.7 million agreement, the company last month reported that SciSafe customers include several Top Five global pharmaceutical companies.
In an interview published last week with Seattle’s Pugent Sound Business Journal, BioLife CEO Mike Rice said the company’s storage technology would not be used for transport of the Covid-19 vaccine, but declined to add further details about the newly signed contract.
BioLife is a developer and supplier of bioproduction tools and services for cell and gene therapies. SciSafe, acquired in September, is expected to contribute approximately $9 million in incremental revenue in 2021, according to BioLife.